Bioheart
Bioheart is a biotech company that focuses on the development of effective cell technologies to treat cardiovascular diseases.
Business Model:
Revenue: $0
Employees: 11-50
Rankings
Industries / Tags:
Detailed Bioheart Information
Geographic Data
Address:
City: Sunrise
State: Florida
Zip:
Country: United States
Financial Info
Stage:
post ipo equity
Raised Last:
$3M
Raised Total:$20M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Bioheart, Inc. is dedicated to advancing the field of regenerative medicine by offering the highest quality technology, cellular treatments and training. Specific to biotechnology, Bioheart, Inc. specializes in the discovery, development and commercialization of autologous cellular therapies that treat a wide variety of degenerative diseases. Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry by delivering stem cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions, chronic and acute heart damage, peripheral vascular disease and other issues. Bioheart&s;s goals are to improve a patient’s quality of life by regenerating their damaged tissue, when possible, and by reducing health care costs and hospitalizations. Bioheart’s leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient&s;s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.
Contact Phone:
Contact Email:
Bioheart went public on 2/20/2008 on the OTCQB
Listed Exchange:
OTCQB
IPO Date:
2/20/2008
Ticker Symbol:
USRM
IPO Price:
$5.2/share
Amount Raised:
$6M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 6/2013 | Post-IPO Equity | $467.5k | 9/2005 | Venture Round | $0 |
Magellan Bioscience Group BioMedPartners Advent-Morro Equity Partners Magellan Bioscience Group BioMedPartners Advent-Morro Equity Partners |
6/2001 | Venture Round | - |
Guidant Guidant Guidant Guidant |
8/2010 | Post-IPO Equity | $234k | 8/2008 | Post-IPO Equity | 1 | $1M |
Rogers Communications Rogers Communications Rogers Communications |
10/2014 | Post-IPO Equity | 1 | $3M |
Magna Magna Magna Magna |
6/2011 | Post-IPO Equity | $145k | 3/2011 | Post-IPO Equity | $100k | 9/2005 | Venture Round | 3 | $15M |
Magellan Bioscience Group BioMedPartners Advent-Morro Equity Partners Magellan Bioscience Group BioMedPartners Advent-Morro Equity Partners |
6/2001 | Venture Round | 1 | - |
Guidant Guidant Guidant Guidant |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
